Processing

Please wait...

Settings

Settings

Goto Application

Offices all Languages Stemming false Single Family Member true Include NPL false

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC:C07H

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.WO/2021/083384LOW MOLECULAR WEIGHT CHONDROITIN SULFATE, COMPOSITION CONTAINING SAME, AND PREPARATION METHOD THEREFOR AND USE THEREOF
WO 06.05.2021
Int.Class C12P 19/14
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
19Preparation of compounds containing saccharide radicals
14produced by the action of a carbohydrase, e.g. by alpha-amylase
Appl.No PCT/CN2020/126003 Applicant NANJING XINLANG ENTERPRISE MANAGEMENT CONSULTING CO.,LTD. Inventor ZHANG, Haoning
Disclosed are a low molecular weight chondroitin sulfate and a preparation method therefor. The method comprises: using a macromolecular chondroitin sulfate as a raw material, and subjecting same to production processes of chondroitin sulfate lyase degradation, deproteinization, filtration, sterilization, drying, etc., so as to obtain a low molecular weight chondroitin sulfate with an average molecular weight less than 1000 daltons. The chondroitin sulfate has a narrow molecular weight distribution range, wherein chondroitin sulfate disaccharides account for 43-60%; chondroitin sulfate tetrasaccharides account for 30-45%; the sum of the content of chondroitin sulfate disaccharides and chondroitin sulfate tetrasaccharides is greater than 87%; the total content of oligosaccharides in the low molecular weight chondroitin sulfate is at least 97%; and the content of protein does not exceed 0.5%. Compared with common commercially available macromolecular chondroitin sulfate, the product has a more obvious repair effect on chondrocytes damaged by 1 mM hydrogen peroxide within the concentration of 50-100 μg/mL. The product has a strong repair ability with a repair rate between 14% and 23%, and can be used to treat joint injuries and is an important raw material for medical products, health care products, cosmetics, foods, etc.
2.20210130182NANOPARTICLE COMPOSITION AND METHOD OF USE AND MANUFACTURE
US 06.05.2021
Int.Class C01G 5/00
CCHEMISTRY; METALLURGY
01INORGANIC CHEMISTRY
GCOMPOUNDS CONTAINING METALS NOT COVERED BY SUBCLASSES C01D OR C01F94
5Compounds of silver
Appl.No 17086374 Applicant Regina VERTELOVA Inventor Regina VERTELOVA

The invention is directed to a composition of metal particles and methods of manufacturing and using the composition in the treatment of microbial infections and cancer. The particles can be nanoparticles having coupled thereto at least one of a surfactant, an antibiotic, and a drug. The particles of the invention achieve enhanced stability, enhanced cytotoxicity, and enhanced antimicrobial activity through novel combinations of metals, surfactants, antibiotics, and drugs.

3.20210130415CHEMICALLY-MODIFIED ADENO-ASSOCIATED VIRUS
US 06.05.2021
Int.Class C07K 14/075
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
005from viruses
01DNA viruses
075Adenoviridae
Appl.No 17142276 Applicant CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE Inventor DAVID DENIAUD

The invention relates to chemically modified adeno-associated (AAV) virus and their use in gene therapy.

4.WO/2021/086889METHODS AND COMPOSITIONS FOR TREATMENT OF CANCER AND INFECTIOUS DISEASES
WO 06.05.2021
Int.Class A61K 39/395
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
Appl.No PCT/US2020/057619 Applicant CHINOOK THERAPEUTICS, INC. Inventor DESBIEN, Anthony Lloyd
The present invention relates to methods and compositions for the treatment of diseases with STING agonists. As described hereinafter, STING activation can be modulated to induce local versus systemic immune activation. At lower doses, intratumoral dosing of STING agonists can produce a robust tumor-specific T-cell response capable of ablating a target tumor at a site distal to the STING agonist administration. At higher doses, the distal anti-tumor response is reduced, and ablation of tumor-draining lymph nodes is observed. It is possible to inhibit this ablation of the tumor-draining lymph nodes by co-administration of a TNF antagonist. This co-administration of STING agonists and TNF antagonists can permit the administration of either increased concentrations of STING agonist or STING agonists having greater activity, while maintaining effective tumor control and generation of an anti-tumor adaptive immune response.
5.WO/2021/081999LOW-MOLECULAR-WEIGHT CHONDROITIN SULFATE AND PREPARATION METHOD THEREFOR
WO 06.05.2021
Int.Class C12P 19/14
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
19Preparation of compounds containing saccharide radicals
14produced by the action of a carbohydrase, e.g. by alpha-amylase
Appl.No PCT/CN2019/115120 Applicant NANJING HANXIN PHARMACEUTICAL TECHNOLOGY CO. LTD. Inventor WANG, Yin
Disclosed are a low-molecular-weight chondroitin sulfate and a preparation method therefor. Macromolecular chondroitin sulfate is used as a raw material. A low-molecular-weight chondroitin sulfate having an average molecular weight of less than 1000 daltons can be obtained by means of a production process comprising chondroitin sulfate lyase degradation, deproteinization, filtration sterilization, drying, etc. With respect to the low-molecular-weight chondroitin sulfate, the molecular weight distribution range is narrow, the proportion of chondroitin sulfate disaccharide is 43% to 60%, the proportion of chondroitin sulfate tetrasaccharide is 30% to 45%, the sum of the contents of the chondroitin sulfate disaccharide and the chondroitin sulfate tetrasaccharide is greater than 87%, the total content of oligosaccharides in the low-molecular-weight chondroitin sulfate is not less than 97%, and the protein content is not more than 0.5%. Compared with common marketed macromolecular chondroitin sulfate, the product has, at a concentration of 50 μg/mL to 100 μg/mL, a more obvious repairing effect on chondrocytes damaged by 1 mM hydrogen peroxide, has a strong repairing ability and a repair rate between 14% and 23%, and can be used to treat joint injuries, and same is thus an important raw material for medical products, healthcare products, cosmetics, food product, etc.
6.WO/2021/085509NUCLEOSIDE DERIVATIVE AND USE THEREOF
WO 06.05.2021
Int.Class A61K 48/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
48Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Appl.No PCT/JP2020/040526 Applicant NATIONAL UNIVERSITY CORPORATION TOKAI NATIONAL HIGHER EDUCATION AND RESEARCH SYSTEM Inventor UENO,Yoshihito
A nucleoside derivative represented by formula (1) or a salt thereof. In the formula, R1 represents an alkoxy group, a hydrogen atom or a halogen atom; R2 and R4 may be the same as or different from each other and independently represent a hydrogen atom, a protecting group for a hydroxyl group, a phosphoric acid group, a protected phosphoric acid group, or -P(=O)nR5R6 (wherein n represents 0 or 1, and R5 and R6 may be the same as or different from each other and independently represent any one group selected from a hydrogen atom, a hydroxyl group, a protected hydroxyl group, a mercapto group, a protected mercapto group, an alkoxy group, a cyanoalkoxy group, an amino group and a substituted amino group, provided that, when n represents 1, the case where each of R5 and R6 represents a hydrogen atom is excluded); R3 represents -(CH2)mNHR7 (wherein m represents an integer of 1 to 6, and R7 represents a hydrogen atom, an alkyl group, an alkenyl group, or a protecting group for an amino group); and B represents a purin-9-yl group, a 2-oxo-pyrimidin-1-yl group, a substituted purin-9-yl group or a substituted 2-oxo-pyrimidin-1-yl group.
7.WO/2021/085644METHOD FOR MANUFACTURING REVAUDIOSIDE-D-CONTAINING CRYSTALLIZED PRODUCT, AND REVAUDIOSIDE-D-CONTAINING CRYSTALLIZED PRODUCT
WO 06.05.2021
Int.Class B01D 9/02
BPERFORMING OPERATIONS; TRANSPORTING
01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
DSEPARATION
9Crystallisation
02from solutions
Appl.No PCT/JP2020/040975 Applicant SUNTORY HOLDINGS LIMITED Inventor URAI Soichiro
There is demand for a novel method for manufacturing a RebD crystallized product. The present invention provides a method for manufacturing a RebD-containing crystallized product, characterized in including: a step for mixing a stevia plant-derived crude product having a total steviol glycoside content of 50-95 mass%, and containing at least RebA and RebD, in a solvent containing ethanol and having a methanol concentration of 1 mg/L or less, and adjusting a crystallization solution; and a step for cooling the crystallization solution under stirring and causing RebD to precipitate.
8.20210130390CD73 INHIBITORS
US 06.05.2021
Int.Class C07H 19/23
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
19Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro derivatives thereof
02sharing nitrogen
04Heterocyclic radicals containing only nitrogen as ring hetero atom
23Heterocyclic radicals containing two or more heterocyclic rings condensed among themselves or condensed with a common carbocyclic ring system, not provided for in groups C07H19/14-C07H19/22222
Appl.No 17114993 Applicant ORIC Pharmaceuticals, Inc. Inventor Xiaohui DU

Described herein are CD73 inhibitors and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for the treatment of cancer, infections, and neurodegenerative diseases.

9.WO/2021/086816GALECTIN-3 INHIBITING C-GLYCOSIDES
WO 06.05.2021
Int.Class C07D 405/04
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
405Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
02containing two hetero rings
04directly linked by a ring-member-to-ring- member bond
Appl.No PCT/US2020/057461 Applicant GLYCOMIMETICS, INC. Inventor MAGNANI, John L.
Compounds, compositions, and methods for treatment and/or prevention of at least one disease, disorder, and/or condition by inhibiting binding of galectin-3 to ligands are disclosed. For example, inhibitors of galectin-3 are described and pharmaceutical compositions comprising at least one such agent is described.
10.WO/2021/087431GOLD NANOPARTICLES/NANOSHELLS IMMUNE CONJUGATES FOR ENHANCED IMMUNOTHERAPY AND PHOTOTHERMAL THERAPY FOR HEMATOLOGIC MALIGNANCIES
WO 06.05.2021
Int.Class C07H 21/00
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
21Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
Appl.No PCT/US2020/058474 Applicant NORTHWESTERN UNIVERSITY Inventor LIN, Adam, Y.
Disclosed herein are CpG conjugated nanoparticles for immunotherapy and photothermal therapy. The composition comprises class B CpG conjugated nanoparticles and/or a class C CpG conjugated nanoparticles where the class B CpG conjugated nanoparticles comprises a nanoparticle core and a class B CpG conjugated thereto and the class C CpG conjugated nanoparticles comprises a nanoparticle core and a class C CpG conjugated thereto.